A better understanding of the inflammatory mechanisms of rare RIPK1-associated monogenic diseases may help to develop more targeted therapies that could be used for a series of diseases, including rare neurodegenerative, autoimmune (psoriasis, ulcerative colitis and arthritis), acute ischemic diseases and other conditions such as sepsis and pancreatic ductal adenocarcinoma (54, 84). This evidence concerns the gene RIPK1 and ulcerative colitis.